TRex Bio Inc.
TRXBHealthcare|Medical - Pharmaceuticals|US
$13.26
+0.27 (+2.08%)
About
Trex Bio, Inc. engages in the manufacture of immunotherapies for autoimmune and inflammatory diseases. It focuses on studying the regulation of tissue inflammation to develop breakthrough medicines. The company was founded by Houman Ashrafian, Adil Daud, Wilson Liao, Diane Mathis, Drew Pardoll, Michael Rosenblum, Alison Simmons, and Jim Wells in May 24, 2018 and is headquartered in South San Francisco, CA.
Stock Price
-5.3%(1Y)
1M
-5.3%
3M
-5.3%
6M
-5.3%
YTD
-5.3%
1Y
-5.3%
3Y
-5.3%
5Y
-5.3%
Pipeline Summary
1 total trials1
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Recruiting: 1
Active Trials (1)
Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis
NCT06934252Moderate-to-severe Atopic Dermatitis
Phase 1Recruiting
Enrollment: 115 participants
Key Facts
Market Cap$110.5M
Employees60
CEOMarion Johnston Erwin
IPO DateOct 9, 2026
Beta0.00
52-Week Range$12.5 – $16.56
Avg Volume164,455
ExchangeNASDAQ
Websitetrex.bio
Ownership
Shares Outstanding8.3M
Recent Insider Trades
Alexandria Venture Investments, LLCBUY
Oct 13, 2026178,571 shares @ $14.00
Alexandria Venture Investments, LLCCONVERSION
Oct 13, 20261,167,930 shares
Alexandria Venture Investments, LLCCONVERSION
Oct 13, 20261,033,541 shares
Alexandria Venture Investments, LLCCONVERSION
Oct 13, 20263,480,387 shares
MARCUS JOEL SCONVERSION
Oct 13, 202641,871 shares
Recent News
TRexBio Announces Closing of Initial Public Offering
Oct 13, 2026 · globenewswire.com
TRexBio Announces Pricing of Initial Public Offering
Oct 8, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:37 AM